

Resource Summary Report

Generated by ASWG on Aug 10, 2026

Brilliant Violet 510(TM) anti-human CD3

RRID:AB_2563468

Type: Antibody

Proper Citation

BioLegend Cat# 300448, RRID:AB_2563468

Antibody Information

URL: http://antibodyregistry.org/AB_2563468

Proper Citation: BioLegend Cat# 300448, RRID:AB_2563468

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 510(TM) anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_2563468

Vendor: BioLegend

Catalog Number: 300448

Alternative Catalog Numbers: 300447

Record Creation Time: 20250820T063236+0000

Record Last Update: 20250821T002338+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 510(TM) anti-human CD3.

No alerts have been found for Brilliant Violet 510(TM) anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Halvorson T, et al. (2026) Reproducible detection of antigen-specific T cells and Tregs via standardized and automated activation-induced marker assay workflows. Cell reports methods, 6(7), 101458.

Liu SX, et al. (2025) Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma. Cell reports. Medicine, 6(7), 102200.

Zhang L, et al. (2025) KLRG1 re-defines a leukemic clone of CD8 effector T cells sensitive to PI3K inhibitor in T cell large granular lymphocytic leukemia. Cell reports. Medicine, 6(4), 102036.

Thisted T, et al. (2025) Conditionally Active CD28xVISTA Bispecific Antibodies Promote Myeloid-Driven T-cell Activation. Cancer immunology research, 13(12), 1956.

Morton JJ, et al. (2025) Autologous Thymic Organoids Support Functional T-cell Education and Enhance Antitumor Immunity in Humanized Mice with Melanoma Xenografts. Cancer research communications, 5(11), 2053.

Ma R, et al. (2024) Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell reports. Medicine, 5(7), 101628.

MacDonald L, et al. (2024) Synovial tissue myeloid dendritic cell subsets exhibit distinct tissue-niche localization and function in health and rheumatoid arthritis. Immunity, 57(12), 2843.

Prokhnevskaya N, et al. (2023) CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity, 56(1), 107.

Ma K, et al. (2023) CEA cell adhesion molecule 5 enriches functional human hematopoietic stem cells capable of long-term multi-lineage engraftment. iScience, 26(12), 108561.

Santegoets SJ, et al. (2023) The combined HPV16-E2/E6/E7 T cell response in oropharyngeal cancer predicts superior survival. *Cell reports. Medicine*, 4(11), 101262.

Reuschl AK, et al. (2022) HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory T cells. *Cell reports*, 39(2), 110650.

Chan KL, et al. (2022) Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses. *Cancer cell*, 40(10), 1190.

Mathewson ND, et al. (2021) Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. *Cell*, 184(5), 1281.

Bergamaschi L, et al. (2021) Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. *Immunity*, 54(6), 1257.

Pušnik J, et al. (2021) Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4+ T cell help. *Cell reports*, 35(13), 109320.

Szabo PA, et al. (2021) Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. *Immunity*, 54(4), 797.

Caduff N, et al. (2021) KSHV infection drives poorly cytotoxic CD56-negative natural killer cell differentiation in vivo upon KSHV/EBV dual infection. *Cell reports*, 35(5), 109056.

Martinez-Fabregas J, et al. (2020) CDK8 Fine-Tunes IL-6 Transcriptional Activities by Limiting STAT3 Resident Time at the Gene Loci. *Cell reports*, 33(12), 108545.

Dangaj D, et al. (2019) Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. *Cancer cell*, 35(6), 885.

Körner C, et al. (2017) HIV-1-Mediated Downmodulation of HLA-C Impacts Target Cell Recognition and Antiviral Activity of NK Cells. *Cell host & microbe*, 22(1), 111.